Immunological markers of optimal response to natalizumab in multiple sclerosis.
暂无分享,去创建一个
G. Izquierdo | J. Álvarez-cermeño | D. Páramo | E. Roldán | L. Villar | L. Costa-Frossard | M. Lucas | M. García‐Sánchez | M. Espiño | Dolores Páramo
[1] T. Olsson,et al. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab , 2011, Annals of neurology.
[2] G. Comi,et al. Freedom from disease activity in multiple sclerosis , 2010, Neurology.
[3] M. Edström,et al. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid , 2010, Multiple Sclerosis.
[4] C. Polman,et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.
[5] D. Miller,et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy , 2009, Neurology.
[6] E. Merelli,et al. A multifactorial prognostic index in multiple sclerosis , 2008, Journal of Neurology.
[7] F. Barkhof,et al. Cerebrospinal Fluid IgM Index Correlates with Cranial MRI Lesion Load in Patients with Multiple Sclerosis , 2007, European Neurology.
[8] M. Trojano,et al. New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .
[9] M. Trojano,et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.
[10] Michael J. Ramsbottom,et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients , 2006, Journal of Neuroimmunology.
[11] S. Cepok,et al. Immune surveillance in multiple sclerosis patients treated with natalizumab , 2006, Annals of neurology.
[12] A. Bar-Or,et al. Natalizumab effects on immune cell responses in multiple sclerosis , 2006, Annals of neurology.
[13] M. Calabrese,et al. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[14] Ludwig Kappos,et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.
[15] H. Hartung,et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. , 2005, Brain : a journal of neurology.
[16] J. Masjuán,et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. , 2005, The Journal of clinical investigation.
[17] J. Masjuán,et al. An ultrasensitive method for the detection of oligoclonal IgG bands. , 2004, Journal of immunological methods.
[18] J. Masjuán,et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis , 2003, Annals of neurology.
[19] G. Underhill,et al. The Role of Bone Marrow-Derived Stromal Cells in the Maintenance of Plasma Cell Longevity1 , 2002, The Journal of Immunology.
[20] J. Masjuán,et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS , 2002, Neurology.
[21] G. Underhill,et al. Longevity Cells in the Maintenance of Plasma Cell The Role of Bone Marrow-Derived Stromal , 2002 .
[22] J. Masjuán,et al. A sensitive and reproducible method for the detection of oligoclonal IgM bands. , 2001, Journal of immunological methods.
[23] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[24] J. Yagüe,et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS , 2001, Neurology.
[25] F. Sánchez‐Madrid,et al. Differential expression of VLA‐4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active α4β1‐fibronectin receptors upon B cell activation , 1991 .
[26] F. Sánchez‐Madrid,et al. Differential expression of VLA-4 integrin by resident and peripheral blood B lymphocytes. Acquisition of functionally active alpha 4 beta 1-fibronectin receptors upon B cell activation. , 1991, European journal of immunology.
[27] G. Aimard,et al. Oligoclonal "fingerprint" of CSF IgG in multiple sclerosis patients is not modified following intrathecal administration of natural beta-interferon. , 1986, Journal of neurology, neurosurgery, and psychiatry.
[28] A. Lefvert,et al. IgG production within the central nervous system: A critical review of proposed formulae , 1985, Annals of neurology.
[29] P. Forsberg,et al. Reference values for CSF-IgM, CSF-IgM/S-IgM ratio and IgM index, and its application to patients with multiple sclerosis and aseptic meningoencephalitis. , 1984, Scandinavian Journal of Clinical and Laboratory Investigation.
[30] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.